Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Compares the volatility characteristics of risk parity against index funds in retirement planning, highlighting stability and risk exposure.
27,630 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
IREN leaps on a landmark NVIDIA AI Cloud contract and a parallel equity option, signaling a strategic pivot from cryp...
So-Young's Q1 2026 results offer clues about growth momentum and profitability. This article breaks down the numbers,...
June data show existing home sales beat forecasts, signaling ongoing demand strength in 2026. The numbers point to st...
A new Peterson Institute analysis argues that Trump turned dollar into a diplomatic tool, with potential ripple effec...
Cynthia Lummis gave clarity on timing for the CLARITY Act, but the Senate path remains uncertain as lawmakers juggle ...
AMD leads a chip stock rebound with a 7% jump, followed by Intel and Broadcom, as analysts frame the pullback as a bu...
Meta Platforms rides a pivotal thesis: AI compute demand is real, scarce, and driving a company-wide pivot to data in...
A wave of lawsuits accusing social media platforms of harming children's mental health is moving into high-stakes cou...
A nationwide look at housing inventory startling trends reveals sharp market divergence. Texas pockets show rising li...
A trio of overlooked U.S. value stocks combines strong balance sheets with cheap earnings multiples, making them cand...
Micron Technology stands out in a complex memory market. This article breaks down three practical reasons micron bril...